NASDAQ: QNRXQuoin Pharmaceuticals Ltd Stock
$0.51-0.01 (-1.92%)
Updated Oct 14, 2024
QNRX Price
$0.51
Fair Value Price
N/A
Market Cap
$2.03M
52 Week Low
$0.48
52 Week High
$6.18
P/E
N/A
P/B
0.27x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$8.28M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.88
Operating Cash Flow
-$8M
Beta
1.55
Next Earnings
Nov 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
QNRX Overview
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how QNRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QNRX is good value based on its book value relative to its share price (0.27x), compared to the US Biotechnology industry average (6.12x)
P/B vs Industry Valuation
QNRX's cash and short-term investments ($12.57M) cannot cover QNRX's cash burn for the next year ($17.76M), once increasing cash burn (122.31%) is accounted for
Interest Coverage Financials
QNRX's short-term assets ($13.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more QNRX due diligence checks available for Premium users.
Be the first to know about important QNRX news, forecast changes, insider trades & much more!
QNRX News
Valuation
QNRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-124.07x
Market
27.44x
QNRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.27x
Industry
6.12x
QNRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
QNRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.0M
Profit Margin
0%
QNRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$14.1M
Liabilities
$6.6M
Debt to equity
0.88
QNRX's short-term assets ($13.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QNRX's short-term assets ($13.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QNRX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
QNRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
$3.2M
Financing
-$136.3k
QNRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
QNRX vs Biotech Stocks
Quoin Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.